|
REM-422 Clinical Trials
2 actively recruiting trials across 2 locations
Pipeline
Phase 1: 1Phase 1/2: 1
Top Sponsors
- Remix Therapeutics2
Indications
- Cancer2
- Recurrent Adenoid Cystic Carcinoma1
- Metastatic Adenoid Cystic Carcinoma1
- Adenoid Cystic Carcinoma1
- Higher-risk Myelodysplastic Syndromes1
Duarte, California1 trial
Phase 1
San Francisco, California1 trial
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
University of California San Francisco Helen Diller Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.